Genentech News
-
Nintendo Co., maker of the Wii video- gaming system, won a U.S. appeals court ruling that makes it harder for patent-licensing companies to seek an import ban on products as a way to demand royalties.
-
Bristol-Myers Squibb Co. sued Roche Holding AG’s Genentech unit seeking a court order that it doesn’t infringe patents used to make treatments for cancer and autoimmune diseases.
-
Bristol-Myers Squibb Co. sued Roche Holding AG’s Genentech unit seeking a ruling it doesn’t infringe patents used to make treatments for cancer and autoimmune diseases.
-
Microsoft Corp., whose employees gave more money to President Barack Obama’s re-election committee than those at any other company, was the second- largest donor to his January inauguration, contributing $2.1 million, according to new Federal Election Commission filings.
-
Biotechnology companies worldwide boosted profit by 37 percent to a record $5.2 billion in 2012, partly by tempering growth in research-and-development spending, according to Ernst & Young.
-
Several U.S. Supreme Court justices sought a compromise on the decades-old practice of granting patents on human genes, debating a case that could redefine rights throughout the biotechnology and agriculture industries.
-
Inventors who want to emigrate from their native countries put the U.S. as their top destination, according to economists at the World Intellectual Property Organization in Geneva.
-
Bayer AG’s patent on the birth control pill Yaz is invalid, a U.S. appeals court said in a decision ensuring that Actavis Inc. and Novartis AG’s Sandoz unit can sell copies of the contraceptive.
-
A U.S. Supreme Court clash over the patenting of human genes left several justices searching for a middle ground in a case with the potential to redefine rights in the biotechnology and agricultural industries.
-
For 30 years, biotechnology innovators have secured thousands of U.S. patents on genes, defining the legal rights to medical and agricultural products worth hundreds of billions of dollars.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page